Burzynski Research
Burzynski Research Institute, Inc. engages in the research and development of antineoplaston drugs for the treatment of various cancers. The company is involved in the research, production, marketing, promotion, and sale of medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives, and organic acids under the Antineoplastons trade name. It also offers consulting se… Read more
Burzynski Research (BZYR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of November 2025: 12.223x
Based on the latest financial reports, Burzynski Research (BZYR) has a cash flow conversion efficiency ratio of 12.223x as of November 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-823.11K) by net assets ($-67.34K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Burzynski Research - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Burzynski Research's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Burzynski Research Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Burzynski Research ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AIS Resources Ltd
V:AIS
|
-0.077x |
|
Ortin Laboratories Limited
NSE:ORTINLAB
|
0.044x |
|
Nova Net Lease REIT
PINK:NNLRF
|
-0.020x |
|
Bentre Aquaproduct Import and Export JSC
VN:ABT
|
N/A |
|
Sultan Resources Ltd
AU:SLZ
|
-0.038x |
|
Mace Security Intl
PINK:MACE
|
-0.152x |
|
LIVE NATION ENT
BE:3LN
|
-0.369x |
|
PicoCELA Inc. American Depositary Shares
NASDAQ:PCLA
|
-0.664x |
Annual Cash Flow Conversion Efficiency for Burzynski Research (1998–2025)
The table below shows the annual cash flow conversion efficiency of Burzynski Research from 1998 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-02-28 | $-41.64K | $-388.53K | 9.331x | -55.24% |
| 2024-02-29 | $-25.12K | $-523.78K | 20.849x | +14.70% |
| 2023-02-28 | $-13.73K | $-249.52K | 18.177x | +106.74% |
| 2022-02-28 | $1.21K | $-325.10K | -269.567x | -3233.55% |
| 2021-02-28 | $-45.84K | $-394.37K | 8.603x | +147.62% |
| 2020-02-29 | $-152.59K | $-530.11K | 3.474x | +35.80% |
| 2019-02-28 | $-186.65K | $-477.52K | 2.558x | -13.76% |
| 2018-02-28 | $-107.70K | $-319.49K | 2.967x | -68.87% |
| 2017-02-28 | $-33.00K | $-314.51K | 9.530x | +283.54% |
| 2016-02-29 | $-101.02K | $-251.02K | 2.485x | -2.80% |
| 2015-02-28 | $-138.34K | $-353.68K | 2.557x | -12.16% |
| 2014-02-28 | $-150.62K | $-438.36K | 2.910x | -63.29% |
| 2013-02-28 | $-84.66K | $-671.29K | 7.929x | -35.12% |
| 2012-02-29 | $-41.25K | $-504.06K | 12.220x | +23.84% |
| 2011-02-28 | $-51.26K | $-505.76K | 9.867x | -21.48% |
| 2010-02-28 | $-48.48K | $-609.18K | 12.566x | +166.11% |
| 2009-02-28 | $-87.35K | $-412.47K | 4.722x | -25.39% |
| 2008-02-29 | $-58.25K | $-368.65K | 6.329x | -44.29% |
| 2007-02-28 | $-53.18K | $-604.15K | 11.361x | -53.04% |
| 2006-02-28 | $-28.28K | $-684.19K | 24.194x | -33.28% |
| 2005-02-28 | $-20.79K | $-753.98K | 36.265x | +79.75% |
| 2004-02-29 | $-32.63K | $-658.23K | 20.175x | -86.88% |
| 2003-02-28 | $-4.69K | $-720.95K | 153.818x | +866.14% |
| 2002-02-28 | $34.00K | $-682.64K | -20.077x | +12.35% |
| 2001-02-28 | $28.64K | $-656.09K | -22.907x | -138.08% |
| 2000-02-29 | $-14.43K | $-867.93K | 60.152x | -95.73% |
| 1999-02-28 | $-701.00 | $-988.48K | 1410.100x | +29622.04% |
| 1998-02-28 | $-397.33K | $-1.89 Million | 4.744x | -- |